Abbott Pulls Absorb Stent Off The Market, Citing Low Sales
Abbott is giving up on selling its first-generation biosorbable coronary stent, which failed to match the performance of contemporary metallic drug-eluting stents in clinical trials. The company says it will continue working on the next-generation biosorbable stents and continue the ongoing trials of Absorb GT1 BVS.
You may also be interested in...
The EFEMORAL I trial is the first-in-human study of the start-up company’s FlexStep technology in patients with symptomatic femoropopliteal artery disease.
Abbott's defunct Absorb BVS stent's efficacy is noninferior to that of the Xience metallic everolimus-eluting stent, new data presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Diego show. But the risk of thrombotic events was still higher with Absorb. This prompted a discussion among panelists whether bioresorbable stents should still be investigated, given the availability of newer-generation drug-eluting stents, which have shown to be safer.
The 2018 EuroPCR meeting in Paris featured new results from clinical trials of coronary stents from Biotronik, Amaranth, Medtronic, MicroPort, and Hexacath.